Dendreon Reports $106M in Cash at End of September
Luke Timmerman11/7/08
Dendreon said today in its quarterly report that it finished the month of September with $106 million in cash and investments in the bank. The Seattle biotech company (NASDAQ: DNDN) said its net loss in the quarter was $26.8 million. It expects to get final clinical results from a trial of its leading prostate cancer drug candidate, Provenge, by the middle of 2009.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
